Paracetamol (acetaminophen) has been Farmson’s flagship product for over half a century, and the company is widely recognized as the global leader in Paracetamol API manufacturing. Established in 1969, Farmson was the pioneer in manufacturing paracetamol in India. Over the decades, it has grown from humble beginnings into the largest integrated producer of paracetamol in the world, with a production capacity of approximately 53,000 metric tons per annum. This capacity is enormous – equivalent to roughly 96.1 billion standard-dose tablets per year – and means Farmson’s paracetamol “touches almost every human life on the face of the earth” in some way.

Farmson’s dominance in the paracetamol segment is underpinned by a relentless focus on quality and continual improvement. Early on, the company invested in state-of-the-art facilities and stringent quality control, which set it apart from competitors. A major innovation was Farmson’s adoption of the PNCB route (p-nitrochlorobenzene route) for paracetamol synthesis, replacing older methods to achieve higher purity API. Farmson also implemented full backward integration for key raw materials like Para-Amino Phenol (PAP), enabling self-sufficiency and supply stability. By producing PAP in-house via advanced catalytic hydrogenation technology, Farmson reduced dependence on external suppliers (notably reducing reliance on imports) and improved overall sustainability of production.

Today, Farmson supplies nearly 40% of India’s domestic demand for paracetamol API and exports to over 65 countries worldwide. Virtually all major multinational and Indian pharmaceutical companies that manufacture paracetamol-based medicines source from Farmson, a testament to decades of trust and proven reliability. Farmson offers a versatile range of paracetamol grades – from fine and micro-fine powders for suspensions, to granular and high-density grades for tablets and capsules, as well as direct compression (DC) granules. This breadth of grades allows formulators to choose the ideal form for their product, ensuring efficient manufacturing and consistent drug release.

Maintaining global leadership also means adhering to the highest quality and compliance benchmarks. Farmson’s paracetamol facilities are internationally accredited and audited. The company holds WHO-GMP certification and has obtained regulatory approvals such as EDQM (CEP) in Europe, ANVISA registration in Brazil, NMPA approval in China, and drug master file (DMF) registrations in countries like the UK, Ukraine, and Uzbekistan. It is also certified under the Responsible Care program and holds Authorized Economic Operator (AEO T2) status, reflecting its commitment to safety, quality, and responsible operations.

In summary, Farmson’s status as a global paracetamol leader is built on unmatched production capacity, technical innovation, and an unwavering commitment to quality. From pioneering paracetamol manufacturing in 1969 to delivering a significant share of the world’s paracetamol today, Farmson has consistently set industry benchmarks. The company’s journey – focusing on quality, innovation, and expansion – exemplifies how a clear vision and sustained excellence can lead to market leadership. Farmson continues to invest in R&D and process improvements for paracetamol, ensuring that it remains the trusted backbone of pain relief and fever medications globally.